XenaCare Holdings, Inc. (XCHO.OB), a developer of uniquely positioned nutritional products, mass retail products and products for practitioners, recently announced that the company has received the exclusive U.S. license to market and distribute an FDA approved homeopathic treatment for chronic pain.

Chronic pain currently affects more than 50 million people throughout the United States. In 2005, U.S. sales of prescription and non-prescription pain management products totaled more than $20.4 billion.

Frank Rizzo, chief executive officer of XenaCare Holdings, stated, “We are extremely enthusiastic about this product, as it represents one of the first non-narcotic treatments for chronic pain. As we move towards our August launch, we plan to release full details about the product as well as its potential to compete effectively with current opiate-based drugs available on the market.”

Specializing in the marketing and retail distribution of consumer healthcare products, XenaCare Holdings also recently announced the launch of the SunPill, a dietary supplement that helps the skin protect itself from sun damage. The SunPill is currently available at national and online retailers, including RiteAid, CVS, Drugstore.com and Amazon.com.